GEN Exclusives

More »

GEN News Highlights

More »
Sep 24, 2007

Quark Pharmaceuticals Inks a Deal to Advance Preclinical Pipeline of Hearing Loss Compounds

  • Quark Pharmaceuticals and the University of Michigan Kresge Hearing Research Institute report that they will together conduct preclinical studies related to the treatment of acute hearing loss.

    The collaborators will investigate siRNA compounds that inhibit Quark’s target genes for the prevention and treatment of acoustic trauma-induced acute hearing loss.

    Quark reports that it expects to file an IND before the end of 2007 for its first hearing loss drug candidate, AHLi-11, for the prevention of cisplatin-induced ototoxic hearing loss.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »